Allspring Global Investments Holdings LLC Sells 80,841 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Allspring Global Investments Holdings LLC cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 273,661 shares of the biotechnology company’s stock after selling 80,841 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.29% of Sarepta Therapeutics worth $26,389,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. International Assets Investment Management LLC lifted its position in Sarepta Therapeutics by 9,382.5% during the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 11,259 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Sarepta Therapeutics by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company’s stock valued at $1,044,000 after purchasing an additional 8,427 shares during the last quarter. Fifth Third Bancorp lifted its position in Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 924 shares during the last quarter. Handelsinvest Investeringsforvaltning bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $302,000. Finally, DMC Group LLC lifted its holdings in shares of Sarepta Therapeutics by 15.0% in the 4th quarter. DMC Group LLC now owns 3,793 shares of the biotechnology company’s stock worth $366,000 after acquiring an additional 496 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Royal Bank of Canada boosted their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $158.38.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock valued at $2,739,419 in the last three months. 7.40% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Down 1.3 %

Shares of Sarepta Therapeutics stock opened at $122.87 on Friday. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The company’s fifty day simple moving average is $127.46 and its two-hundred day simple moving average is $110.49. The company has a market cap of $11.54 billion, a P/E ratio of -20.08 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.24) EPS. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.